AC Immune - M&A Summary and Business Overview

Life ScienceCompany

AC Immune M&A Summary

AC Immune has acquired 1 company, including 1 in the last 5 years.

AC Immune’s largest acquisition to date was in 2021, when it acquired AFFiRiS - Specific Active Immunotherapy anti-alpha-synuclein Programs for $59M. The Company’s most targeted sectors include life science (100%).

AC Immune Business Overview

Where is AC Immune headquartered?

AC Immune is headquartered in Lausanne, Switzerland.

What is AC Immune’s revenue?

AC Immune disclosed revenue of 15M USD for 2023 and 4M USD for 2022.

How many employees does AC Immune have?

AC Immune has 133 employees.

What sector is AC Immune in?

AC Immune is a life science company.

When was AC Immune founded?

AC Immune was founded in 2003.

M&A Summary

  • M&A Total Activity1
    • M&A Buy Activity1
  • Total Sectors Invested 1
  • Total Countries Invested 1
  • M&A Buy/Sell Connections 1

AC Immune

AC Immune SA

EPFL Innovation Park Building B,
Lausanne, 1015
Switzerland,
+41 21 345 91 21
www.acimmune.com

AC Immune is a clinical-stage biopharmaceutical company that aims to become a global leader in precision medicine for neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and NeuroOrphan indications driven by misfolded proteins. The Company's two clinically validated technology platforms, SupraAntigen and Morphomer, fuel its broad and diversified pipeline of first- and best-in-class assets, which currently features ten therapeutic and three diagnostic candidates, six of which are currently in clinical trials. AC Immune was incorporated in 2003 and is based in Lausanne, Switzerland.


M&A Summary

Buy vs Sell

Year ≤ '19 '20 '21 '22 '23 '24 T
Buy (0.2/yr) # - - 1 - - - 1
vol $59M $59M
Sell (0.0/yr) # - - - - - - 0
  1

Most Recent M&A

Company Date Value Type
AFFiRiS - Specific Active Immunotherapy (SAIT) anti-alpha-synuclein Programs 2021-07-27 59M USD Divestiture
Vienna, Austria
View All >>

M&A by Sector

Sector Buy # Value Sell # Value
Life Science 1 (100%) 59M (100%) - -
Total 1 $59M - -

By Geo

State/Country Buy Value Sell Value
Austria 1 59M - -
Total 1 $59M - -

Deal Values

buy # Total
< $100M 1 $59M
TOTAL $59M
Largest AFFiRiS - Specific Active Immunotherapy (SAIT) anti-alpha-synuclein Programs
$59M (2021-07-27)

M&A Connections

Deals
Acquired from
Strategic(s)
100%
1 (100%)

 Subscribe to unlock this and 207,814
investor and company profiles

Sign-up today to get full access

  • check  Unlimited Searches
  • check  Unlimited Profile Views
  • check  Build and Export Lists of
    • PE Backed Companies
    • Direct Investors & Acquirers
    • Advisors
    • Deals
    • & More

What's Mergr?

We built Mergr to save people the arduous and time-consuming process of tracking when companies are bought, sold, and who currently owns them.

Every day, new opportunities emerge around M&A and we help professionals of all types comb through transactions, investors, and corporate acquirers via an easy-to-use web database that is accessible to anyone.

Try us for 1 week free today!

Mergr, the Easiest-to-Use PE and M&A DB


Key Benefits

  • Stay informed on events in your industry
  • M&A research that takes seconds (not all afternoon)
  • Better understand your customers and prospects
  • Discover active buyers (or sellers)
Search
  • 4.6K Private Equity Firms
  • 200K M&A Transactions
  • 203K Companies Involved in M&A
    (Buyer, Seller, or Target)
  • 3.6K M&A Advisors
    (Investment Banks and Law Firms)
  • 81K M&A Contacts
    (PE and M&A Advisors)

Ready to try?

Join FREE for 1 Week

No obligation. Cancel anytime.

Related Lists for AC Immune

Life Science Companies , Switzerland Companies